Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Timolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Timolol SCHEMBL1587691 | 0.99 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL4912 | 0.99 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL222970 | 0.99 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL2553603 | 0.99 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL8858736 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL5539013 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL11418545 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL16094075 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL7591293 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL8858730 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104274390-A | Timolol long-acting transdermal preparation and application thereof in hemangioma treatment | ZHENG JIAWEI | 2015-01-14 | — | — | CN | claimed |
| CN-115252718-A | Transdermal patch containing timolol and preparation method thereof | 武汉科福新药有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2018033854-A1 | OPHTHALMIC COMPOSITION AND A METHOD FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2018-02-22 | — | — | WO | disclosed |
| CN-104274390-B | A kind of long-acting preparation capable of permeating skin of timolol and its application in hemangioma | 郑家伟 | 2017-06-13 | — | — | CN | disclosed |
| CN-104274390-B | A kind of long-acting preparation capable of permeating skin of timolol and its application in hemangioma | 郑家伟 | 2017-06-13 | — | — | CN | disclosed |
| CN-104274390-A | Timolol long-acting transdermal preparation and application thereof in hemangioma treatment | ZHENG JIAWEI | 2015-01-14 | — | — | CN | disclosed |
| CN-104274390-A | Timolol long-acting transdermal preparation and application thereof in hemangioma treatment | ZHENG JIAWEI | 2015-01-14 | — | — | CN | disclosed |
| US-8652518-B2 | Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation | FINLEY JAHAHREEH (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130273175-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS, INFLAMMATION, AND METABOLIC DYSREGULATION | FINLEY JAHAHREEH (US) | 2013-10-17 | — | — | US | disclosed |
| US-8492334-B2 | Sustained intraocular delivery of drugs from biodegradable polymeric microparticles | YALE UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110189291-A1 | DENDRIMER HYDROGELS | VIRGINIA COMMONWEALTH UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
| US-20100261646-A1 | SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES | YALE UNIVERSITY (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2178502-A2 | SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES | YALE UNIVERSITY (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2008157614-A9 | SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES | UNIV YALE (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008157614-A2 | SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES | YALE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261646-A1 | SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES | MIF, LDHA, MYOC | ADRB2 184/4885ADRB1 83/4885CYP1A2 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.